Biohaven Pharmaceutical (NYSE:BHVN) Issues Q1 2021 Earnings Guidance

Biohaven Pharmaceutical (NYSE:BHVN) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share guidance of – for the period. The company issued revenue guidance of $43.80 million-$43.80 million, compared to the consensus revenue estimate of $36.41 million.

Shares of Biohaven Pharmaceutical stock traded down $4.40 on Tuesday, hitting $71.11. 562,555 shares of the company were exchanged, compared to its average volume of 616,525. Biohaven Pharmaceutical has a 1-year low of $42.74 and a 1-year high of $100.77. The stock has a market capitalization of $4.41 billion, a price-to-earnings ratio of -6.15 and a beta of 1.09. The company has a 50-day moving average price of $71.84 and a 200 day moving average price of $82.10.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings data on Sunday, February 28th. The company reported ($3.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.89) by ($0.73). The company had revenue of $35.10 million for the quarter, compared to analysts’ expectations of $35.01 million. The company’s revenue for the quarter was up 350900.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.85) earnings per share. As a group, sell-side analysts predict that Biohaven Pharmaceutical will post -12.38 earnings per share for the current fiscal year.

A number of research analysts recently commented on the company. Canaccord Genuity decreased their price objective on Biohaven Pharmaceutical from $110.00 to $101.00 and set a buy rating on the stock in a report on Tuesday, January 19th. Piper Sandler boosted their price objective on shares of Biohaven Pharmaceutical from $90.00 to $110.00 and gave the company an overweight rating in a report on Monday, March 1st. William Blair reaffirmed a buy rating on shares of Biohaven Pharmaceutical in a research report on Friday, February 5th. UBS Group started coverage on shares of Biohaven Pharmaceutical in a research report on Wednesday, March 17th. They set a buy rating and a $108.00 price target for the company. Finally, Zacks Investment Research cut Biohaven Pharmaceutical from a hold rating to a sell rating and set a $90.00 price target on the stock. in a research note on Wednesday, February 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $95.75.

In related news, Director John W. Childs acquired 13,157 shares of the business’s stock in a transaction on Wednesday, March 17th. The shares were bought at an average price of $76.00 per share, with a total value of $999,932.00. Also, Director John W. Childs acquired 10,000 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, March 2nd. The shares were bought at an average price of $85.14 per share, with a total value of $851,400.00. Following the transaction, the director now directly owns 2,532,644 shares in the company, valued at approximately $215,629,310.16. The disclosure for this purchase can be found here. 19.10% of the stock is currently owned by insiders.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Further Reading: What are the components of an earnings report?

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with's FREE daily email newsletter.